MedTrace Logo

Efficacy and Safety of Zuberitamab Combined with Bendamustine, Followed by Monotherapy Maintenance, in Treatment-naïve Follicular Lymphoma

NCT06757894 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-01-03

No results posted yet for this study

Summary

This is a prospective, single-arm, multicenter, phase ll clinical trial to evaluate the efficacy and safety of Zuberitamab and Bendamustine combination treatment in treatment-naïve follicular lymphoma patients.

Conditions

  • Follicular Lymphoma (FL)

Interventions

DRUG

Zuberitamab

375 mg/m², administered on Day 1 (D1) of Cycles 1-6 (C1-C6)

DRUG

Bendamustine

90 mg/m², administered on D1-2 of C1-C6

Sponsors & Collaborators

  • Gansu Cancer Hospital

    collaborator OTHER

  • Ganzhou Cancer Hospital

    collaborator UNKNOWN

  • Fifth Affiliated Hospital, Sun Yat-Sen University

    collaborator OTHER

  • Fifth Affiliated Hospital of Guangzhou Medical University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-01
Primary Completion
2028-02-01
Completion
2034-02-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06757894 on ClinicalTrials.gov